Then, the expression levels of ZNF24 and SLC7A5 were detected in 16 selected KRAS mutation tumor tissues and KRAS wild-type tumor tissues from the samples by qPCR and Western blot analysis, and we found that the expression levels of ZNF24 and SLC7A5 were both increased in KRAS mutation patients (Figures 2G–H). Here, KRAS is linked to neoplasm.